Professor Lisa Horvath
Professor Lisa Horvath is the Director of Research and Senior Staff Specialist at the Chris O'Brien Lifehouse and Clinical Researcher heading the Advanced Prostate Cancer Group at the Garvan Institute of Medical Research in The Kinghorn Cancer Centre. She is also the Professor of Medical Oncology (genitourinary cancer) at the University of Sydney and Chair of the Prostate Subcommittee of the Australian and New Zealand Urogenital and Prostate (ANZUP) clinical trials group.
Having completed medical school at the University of Sydney and trained in medical oncology at Royal Prince Alfred Hospital, Lisa subsequently worked at Garvan completing her PhD in translational research in 2004. She was appointed to the senior staff of Royal Prince Alfred Hospital in 2003 (moved to Chris O’Brien Lifehouse in 2013) and has concurrently led an independent research group at Garvan for 15 years as a clinician scientist. She has published >110 original research papers published in peer-reviewed journals in the last 20 years across the fields of cancer biology, biomarkers and clinical trials.
Awards
- 2018
Prize for “Best of the best plenary presentation” - Medical Oncology Group of Australia
- 2004
Medical Oncology Group of Australia / GlaxoSmithKline Travel Grant
- 2002
American Society of Clinical Oncology Merit Award
- 2002
Medical Oncology Group of Australia / GlaxoSmithKline Travel Grant
- 2002
Neupogen / Medical Oncology Group of Australia Advanced Trainee Award
- 2000–2003
- 2000–2003
NHMRC Medical Postgraduate Research Scholarship
- 1999
Medical Oncology Group of Australia / Asta Medica Educational Travel Grant
- 1989
Grafton Elliot Smith Memorial Prize for Anatomy
- 1989
Herbert John Wilkinson Memorial Prize for Anatomy
Selected publications
See all publications- PUBLISHED 24 January 2026Familial Cancer
Delphi panel consensus on genetic testing for prostate cancer in Australia: Whom to test and how?
- PUBLISHED 12 February 2025The Lancet. Oncology
Overall survival and quality of life with [Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial
- PUBLISHED 16 December 2024Therapeutic Advances in Medical Oncology
Evolocumab in metastatic castration-resistant prostate cancer: study protocol for a single-arm, phase II trial, and initial experience with use of a validated lipid biomarker to direct therapy
- PUBLISHED 15 September 2024The Lancet. Oncology
Sequential [Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study
- PUBLISHED 6 July 2024Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research
The Cost-Effectiveness of Germline BReast CAncer Gene Testing in Metastatic Prostate Cancer Followed by Cascade Testing of First-Degree Relatives of Mutation Carriers
